Drug Approval | April 22, 2023
Ajinomoto Bio-Pharma receives FDA approval for high potency fill line
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
TPE tubing is ideal for pharmaceutical bioprocessing applications because it can be welded to existing tubing lines, and heat-sealed to allow for easy, fast, and safe fluid transport in biopharma processes
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Lutio has the potential to offer significant cost savings when available to UK patients.
New deal strengthens Congenica’s presence in India
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Strive to empower public health with disinfection robotics solutions in post-pandemic era
Subscribe To Our Newsletter & Stay Updated
